Nuvation Bio's Q3 Loss Widens, Revenue Jumps on Product Launch

TL;DR

**NUVB is burning cash faster than it's making it, but new product revenue offers a glimmer of hope if they can control expenses.**

AI Summary

Nuvation Bio Inc. reported a net loss of $55.79 million for the three months ended September 30, 2025, an increase from a net loss of $41.21 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss significantly decreased to $168.04 million from $518.49 million in the prior year, primarily due to the absence of a $425.07 million acquired in-process research and development expense from the AnHeart acquisition in 2024. Total revenues for the three months increased to $13.12 million from $0.73 million, driven by $7.72 million in product revenue and $5.40 million in collaboration and license agreements revenue. Research and development expenses rose to $28.85 million for the quarter, up from $27.73 million, and selling, general and administrative expenses increased to $37.36 million from $19.58 million. The company's cash and cash equivalents increased to $98.90 million as of September 30, 2025, from $35.72 million at December 31, 2024, bolstered by $150.00 million from a revenue interest financing agreement. Total liabilities surged to $275.68 million from $76.84 million, largely due to new long-term borrowings and the revenue interest financing agreement.

Why It Matters

Nuvation Bio's significant increase in product revenue to $7.72 million in Q3 2025 marks a critical step towards commercialization, indicating potential market acceptance for IBTROZI™ (taletrectinib). However, the widening quarterly net loss and substantial increase in operating expenses, particularly selling, general and administrative costs, suggest the company is investing heavily in its commercial infrastructure and R&D pipeline. For investors, this signals a high-risk, high-reward scenario: successful market penetration could lead to future profitability, but continued losses and increased debt, including a $150 million revenue interest financing agreement, raise concerns about long-term financial sustainability and dilution risk. The competitive oncology market demands sustained innovation and effective commercialization, making Nuvation Bio's ability to convert R&D into profitable products paramount.

Risk Assessment

Risk Level: high — The company reported a net loss of $55.79 million for Q3 2025 and an accumulated deficit of $1.08 billion as of September 30, 2025, indicating a history of unprofitability. Total liabilities surged from $76.84 million to $275.68 million, largely due to a $150.00 million revenue interest financing agreement and $47.09 million in long-term borrowings, significantly increasing financial leverage and future obligations.

Analyst Insight

Investors should closely monitor Nuvation Bio's ability to scale product revenue and manage its rapidly increasing operating expenses, particularly R&D and SG&A. Given the significant increase in liabilities from the $150 million revenue interest financing agreement, investors should assess the terms of this agreement and its impact on future cash flows and profitability before considering any new positions.

Financial Highlights

debt To Equity

N/A

revenue

$13.12M

operating Margin

N/A

total Assets

N/A

total Debt

$275.68M

net Income

-$55.79M

eps

N/A

gross Margin

N/A

cash Position

$98.90M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $55.79M — Net Loss (Q3 2025) (Increased from $41.21M in Q3 2024, indicating widening quarterly losses.)
• $168.04M — Net Loss (YTD 2025) (Significantly reduced from $518.49M in YTD 2024, primarily due to the absence of a large acquisition expense.)
• $13.12M — Total Revenues (Q3 2025) (Increased from $0.73M in Q3 2024, driven by new product revenue.)
• $7.72M — Product Revenue (Q3 2025) (New revenue stream, indicating initial commercialization efforts.)
• $28.85M — R&D Expenses (Q3 2025) (Increased from $27.73M in Q3 2024, reflecting ongoing pipeline investment.)
• $37.36M — SG&A Expenses (Q3 2025) (Increased from $19.58M in Q3 2024, indicating higher commercialization and administrative costs.)
• $98.90M — Cash and Cash Equivalents (Sept 30, 2025) (Increased from $35.72M at Dec 31, 2024, boosted by financing activities.)
• $275.68M — Total Liabilities (Sept 30, 2025) (Significantly increased from $76.84M at Dec 31, 2024, due to new financing agreements.)
• $150.00M — Revenue Interest Financing Agreement (New financing obtained in YTD 2025, contributing to increased liabilities.)
• $1.08B — Accumulated Deficit (Sept 30, 2025) (Reflects continued historical losses.)

Key Players & Entities

• Nuvation Bio Inc. (company) — registrant
• AnHeart Therapeutics Ltd. (company) — acquired company
• IBTROZI™ (taletrectinib) (product) — key product candidate
• $55.79 million (dollar_amount) — net loss for Q3 2025
• $41.21 million (dollar_amount) — net loss for Q3 2024
• $168.04 million (dollar_amount) — net loss for nine months ended Sept 30, 2025
• $518.49 million (dollar_amount) — net loss for nine months ended Sept 30, 2024
• $425.07 million (dollar_amount) — acquired in-process research and development expense in 2024
• $13.12 million (dollar_amount) — total revenues for Q3 2025
• $7.72 million (dollar_amount) — product revenue for Q3 2025

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $1.08 billion as of September 30, 2025. This indicates a history of substantial losses, which raises concerns about long-term financial sustainability and the need for continued funding.
• Substantial Increase in Liabilities [high — financial]: Total liabilities surged to $275.68 million as of September 30, 2025, from $76.84 million at December 31, 2024. This increase is primarily due to new long-term borrowings and a $150.00 million revenue interest financing agreement, increasing financial leverage and potential debt servicing obligations.
• Increasing Operating Expenses [medium — operational]: Research and development expenses rose to $28.85 million for Q3 2025, and SG&A expenses increased to $37.36 million. This trend suggests growing operational costs associated with pipeline development and commercialization efforts, which could further pressure profitability.
• Dependence on Future Financing [high — financial]: The company's substantial accumulated deficit and ongoing net losses indicate a continued reliance on external financing to fund operations and development. Any disruption in accessing capital markets could severely impact its ability to continue operations.
• Drug Development and Approval Risks [high — regulatory]: As an oncology company, Nuvation Bio faces inherent risks in the lengthy and expensive process of drug development, clinical trials, and regulatory approval. Failure to achieve successful outcomes in any of these stages can lead to significant financial write-offs and delays.

Industry Context

Nuvation Bio operates in the highly competitive global oncology sector, focusing on developing novel cancer therapies. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial efficacy, and successful commercialization strategies, often requiring substantial capital.

Regulatory Implications

As a biopharmaceutical company, Nuvation Bio is subject to rigorous regulatory scrutiny from bodies like the FDA. Delays or failures in clinical trials or the approval process can have severe financial and operational consequences. Compliance with evolving healthcare regulations and data privacy laws is also critical.

What Investors Should Do

1. Monitor R&D pipeline progress and clinical trial results closely.
2. Analyze the sustainability of the current cash burn rate against the increased liabilities.
3. Evaluate the revenue generation from new product sales and collaboration agreements.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $55.79M, increased revenue to $13.12M, and cash position of $98.90M.
• 2025-01-01: Start of Fiscal Year 2025 — Beginning of the period with significant revenue growth and financing activities.
• 2024-04-09: AnHeart Acquisition Date — Acquisition that led to a significant one-time R&D expense in 2024, impacting year-over-year comparisons.
• 2024-12-31: End of Fiscal Year 2024 — Cash position was $35.72M, and total liabilities were $76.84M.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability and its reliance on external funding to cover past losses, standing at $1.08 billion as of September 30, 2025.)

Revenue Interest Financing Agreement

A type of financing where investors provide capital in exchange for a percentage of the company's future revenue. (Nuvation Bio secured $150.00 million through such an agreement, significantly increasing its liabilities and cash position.)

Acquired in-process research and development

Costs associated with research and development projects acquired in a business combination that have not yet reached technological feasibility and have no alternative future use. (A $425.07 million expense related to the AnHeart acquisition in 2024 significantly impacted prior year net loss figures.)

Collaboration and License Agreements

Contracts where a company partners with others to develop or commercialize products, often involving upfront payments, milestones, and royalties. (This revenue stream contributed $5.40 million to Q3 2025 revenues, indicating progress in strategic partnerships.)

Year-Over-Year Comparison

Compared to the prior year, Nuvation Bio has seen a significant increase in revenue for Q3 2025, reaching $13.12 million from $0.73 million, driven by new product sales and collaboration agreements. However, quarterly net losses have widened to $55.79 million from $41.21 million, largely due to a substantial increase in SG&A expenses to $37.36 million from $19.58 million, indicating higher commercialization and administrative costs. While the year-to-date net loss has dramatically decreased due to the absence of a large acquisition expense from 2024, the company's liabilities have surged to $275.68 million from $76.84 million, reflecting new financing activities.

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share Redeemable Warran
• $11.50 — Common Stock at an exercise price of $11.50 per share NUVB NUVB.WS The New Yo

Filing Documents

• nuvb-20250930.htm (10-Q) — 3503KB
• nuvb-ex31_1.htm (EX-31.1) — 18KB
• nuvb-ex31_2.htm (EX-31.2) — 18KB
• nuvb-ex32_1.htm (EX-32.1) — 10KB
• nuvb-ex32_2.htm (EX-32.2) — 8KB
• 0001193125-25-262605.txt ( ) — 12316KB
• nuvb-20250930.xsd (EX-101.SCH) — 1414KB
• nuvb-20250930_htm.xml (XML) — 2409KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "will" and "would," or the negative of these terms or other similar expressions intended to identify statements about the future. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about: our plans to develop and commercialize IBTROZI TM (taletrectinib) and our other product candidates; our ability to obtain regulatory approval of our current and future product candidates, and to maintain regulatory approval for IBTROZI and our future approved products; our expectations regarding the potential market size and the rate and degree of market acceptance of IBTROZI and our current and future product candidates; our ability to recognize the anticipated benefits of the Merger (as defined below), which may be affected by, among other things, competition and our ability to grow and manage growth profitably; the initiation, timing, progress and results of our current and future preclinical studies and clinical trials, as well as our research and development programs; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to successfully acquire or in-license additional product candidates on reasonable terms; our ability to maintain and establish collaborations or obtain additional funding; our continued reliance on third parties to conduct clinical trials of ou

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Consolidated Balance Sheets 1 Consolidated Statements of Operations and Comprehensive Loss 2 Consolidated Statements of Stockholders' Equity 3 Consolidated Statements of Cash Flows 5 Notes to Unaudited Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 34 PART II. OTHER INFORMATION 35 Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 88 Item 3. Defaults Upon Senior Securities 88 Item 4. Mine Safety Disclosures 88 Item 5. Other Information 88 Item 6. Exhibits 89

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

Financi al Statements

Item 1. Financi al Statements. NUVATION BIO INC. and Subsidiaries Consolidated B alance Sheets (In thousands, except share and per share data) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 98,897 $ 35,723 Accounts receivable, net of allowance for credit loss of $ nil 8,323 12,722 Inventory 5,710 — Prepaid expenses and other current assets 8,925 7,271 Marketable securities 450,148 466,969 Interest receivable on marketable securities 5,527 3,570 Total current assets 577,530 526,255 Property and equipment, net of accumulated depreciation of $ 1,110 and $ 874 , respectively 560 586 Intangible assets, net of accumulated amortization of $ 1,390 and $ 448 , respectively 11,680 4,622 Operating lease right-of-use assets 4,329 2,402 Other non-current assets 7,462 6,761 Total assets $ 601,561 $ 540,626 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 15,360 $ 6,348 Current operating lease liabilities 1,871 1,663 Contract liabilities, current portion 6,721 11,117 Liability related to revenue interest financing agreement 5,982 — Short-term borrowings 5,618 6,283 Accrued expenses 32,579 32,833 Total current liabilities 68,131 58,244 Warrant liability 1,738 2,053 Contract liabilities, net of current portion 11,130 15,572 Non-current operating lease liabilities 2,970 969 Non-current liability related to revenue interest financing agreement, net of current portion and deferred financing costs of $ 4,450 and $ 0 as of September 30, 2025 and December 31, 2024 144,621 — Long-term borrowings, net of current portion and deferred financing costs of $ 3,161 and $ 0 as of September 30, 2025 and December 31, 2024 47,089 — Total liabilities 275,679 76,838 Commitments and contingencies (Note 11) Stockholders' equity Class A and

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 1. Nature of Operations Nuvation Bio Inc. and subsidiaries ("Nuvation Bio"), a Delaware corporation, is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York, San Francisco, Boston and Shanghai. On February 10, 2021, (the "Closing Date"), Nuvation Bio Inc., a Delaware corporation ("Legacy Nuvation Bio"), Panacea Acquisition Corp. ("Panacea"), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea ("Merger Sub") consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 ("Merger Agreement"). Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the "Merger") and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the "Company" or "Nuvation Bio"). On April 9, 2024, (the "Acquisition Date"), the Company completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands ("AnHeart"), pursuant to that certain Agreement and Plan of Merger (the "AnHeart Merger Agreement"), by and among the Company, AnHeart, Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company, and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a w

View Full Filing

View this 10-Q filing on SEC EDGAR